A Translational Neuroscience & Computational Evaluation of a D1R Partial Agonist for Schizophrenia (TRANSCENDS): Rationale and Study Design of a Brain-Based Clinical Trial
Clara Fonteneau, Zailyn Tamayo, Ally Price, Lining Pan, Yvette Afriyie-Agyemang, Shriya Agrawal, Audrey Butler, Courtney Cail, Monica Calkins, Srinivas Chakilam, Kimberlee Forselius-Bielen, Geena Fram, Allea Frazier, Roberto Gil, Preetika Govil, David L. Gray, Jack Grinband, Ruben C. Gur, Natalka K. Haubold, Zachary Heffernan, Larry Kegeles, Christian Kohler, Chenyang Lin, Jing Lu, Megan Mayer, Phuong Pham, Greg Perlman, Masih Rahmati, Mohini Ranganathan, Nicole P. Santamauro, Christopher T. Schutte, Alexandria Selloni, Jared Van Snellenberg, Toral Surti, Daniel H. Wolf, Catrin Zharyy, TRANSCENDS Group, Anissa Abi-Dargham, Raquel E. Gur, Jeffrey A. Lieberman, Joshua T. Kantrowitz, Alan Anticevic, Youngsun T. Cho, John H. Krystal
medRxiv 2025.04.18.25326082; doi: https://doi.org/10.1101/2025.04.18.25326082
